Trial Group - Lung

Advanced non-small cell lung cancer (NSCLC) who are at least 18 years of age.

This trial will investigate the utility of biomarker-based triage for patients with advanced non-small cell lung cancer (NSCLC) without prior systemic therapy.

Participants with previously untreated, stage IV, metastatic non-small cell lung cancer whose tumours are PD-L1 positive (TPS ≥ 50%)

The purpose of this study is to determine the efficacy of pembrolizumab given in combination with either ipilimumab or placebo as first-line treatment in participants with metastatic non-small cell lung cancer (NSCLC). The primary hypothesis of this study is that overall survival (OS) and/or progression-free survival (PFS) is prolonged in participants who receive pembrolizumab and ipilimumab compared to those who receive pembrolizumab and placebo.

Patients with Advanced or Metastatic Non-Small Cell Lung Cancer With Tumors Expressing PD-LI

The primary objective of the study is to compare the progression-free survival (PFS) of REGN2810 plus standard-of-care platinum-based doublet chemotherapy combination therapy or REGN2810 plus ipilimumab combination therapy with standard-of-care platinum -based doublet chemotherapy in the first-line freatment of patients with advanced squamous or non-squamous non-small cell lung cancer (NSCLC) in the subgroup of patients whose tumors express programmed cell death ligand I (PD-L l) in 1% to

Patients with advanced stage RET-rearranged NSCLC, treated with at least one platinum based systemic chemotherapy regimen.

The primary objective is to assess the efficacy of alectinib in terms of best overall response (OR) assessed by RECIST 1.1., from the start of trial treatment across all time points until the end of trial treatment

Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer

To assess the efficacy and safety of Pembrolizumab (MK-3475) with platinum doublet chemotherapy as neoadjuvant/adjuvant therapy for participants With resectable stage IIB or IIIA non-small cell lung cancer.

Advanced Non-Small Cell Lung Cancer (NSCLC) with no prior systemic anti-cancer therapy.

To evaluate the effectiveness of nivolumab plus ipilimumab combined with chemotherapy compared to chemotherapy alone.

Treatment-naïve locally advanced or metastatic non-small cell lung cancer (NSCLC)

To compare the effectiveness of atezolizumab versus single agent chemotherapy.

Advanced non-small cell lung cancer (NSCLC) with EGFRm and T790m.

To compare osimertinib and bevacizumab versus osimertinib alone.

Extensive-stage Small Cell Lung Cancer (ED SCLC).

To evaluate if rovalpituzumab tesirine improves progression-free and overall survival.

Non-Small Cell Lung Cancer

The purpose of this trials is to demonstrate the superiority of avelumab versus platinum-based doublet.